Photo taken from Toni Choueiri/Twitter
Oct 24, 2023, 13:48
Toni Choueiri: Dr. Arlene Siefker-Radtkr presents the results of THOR
Quoting Toni Choueiri, the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, on X/Twitter:
“To kick-off an exciting GU proffered session: Dr. Arlene Siefker-Radtkr presents the results of THOR:
– No OS benefit for erdafitinib vs pembro,
– Increased response rate with erdafitinib,
– While fewer responses to pembro, response is more durable.”
Source: Toni Choueiri/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 19, 2024, 10:18
Nov 19, 2024, 10:05
Nov 19, 2024, 09:53
Nov 19, 2024, 09:44
Nov 19, 2024, 09:40
Nov 19, 2024, 09:28